Compare Novartis AG (NVS) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Novartis AG trades at $152.86 (market cap $295.37B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.65 (market cap $46.84B). The key difference: Novartis AG is far larger — about 6.3× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Novartis AG pays a 3.07% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| NVS | TTWO | |
|---|---|---|
Market Cap | $295.37B | $46.84B |
Sector | Health | Media |
52-Week High | $168.62 | $262.29 |
52-Week Low | $119.31 | $189.69 |
Enterprise Value | $336.69B | $47.96B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Take-Two Interactive (TTWO) trades at $253.57, up 2.87% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters despite a net loss, driven by NBA 2K and Grand Theft Auto (GTA) performance. Cash flow improved in 2025 due to financing activities, while debt levels remain elevated. Investor focus centers on the November 2026 GTA VI launch, with preorders termed 'unprecedented' by management (Bloomberg, August 7, 2026).
The outlook hinges on GTA VI's success, offering substantial upside to the $300.55 consensus target, but execution risks and high valuation multiples (P/S 6.94, EV/EBITDA 38.35) warrant caution. Near-term volatility may persist amid earnings uncertainty, though institutional bullishness (78.95% buy ratings) underscores long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
